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The mean PTV homogeneity index (HI) was 0.14±0.04 for SA 
and 0.09±0.03 for DA. For the OAR sparing, there was no 
significant difference between the SA and DA. A significantly 
difference was observed in the number of MUs and the 
treatment time, SA presents a reduction of 10.3% and 24.5% 
respectively. 
 
Conclusion: SA showed no significantly difference in PTV 
coverage and OAR sparing compared with DA, however, the 
CI and HI of DA were better than those of SA. SA improved 
the greater treatment efficiency, and achieved less MUs 
number. In order to reduce patient treatment time, SA is 
worth to consider. 
 
EP-1672  
mARC vs. IMRT treatment of prostate and head-and-neck 
cancer with flat and FFF energies 
Y. Dzierma
1Universitätsklinikum des Saarlandes, Department of 
Radiation Oncology, Homburg/Saar, Germany 
1, K. Bell1, F. Nuesken1, J. Palm1, J. Fleckenstein1, 
N. Licht1, C. Rübe1 
 
Purpose or Objective: The modulated arc (mARC) is a VMAT-
like rotational technique specifically designed for “burst 
mode” delivery of high dose rates. Only few studies have 
assessed the performance of this radiotherapy modality, and 
it is unclear how efficient it will prove for target volumes of 
high vs. low complexity. We therefore present a planning and 
delivery study for two frequent clinical applications: a 
relatively simple target volume for prostate cancer without 
lymph node involvement and a highly complex target volume 
for hypopharynx cancer. In each case, plan quality, 
treatment time and scattered dose are compared for mARC 
vs. IMRT using flat or flattening-filter-free (FFF) beams. 
 
Material and Methods: Contours were retrospectively 
created for 10 prostate cancer patients and 8 head-and-neck 
cancer patients treated at our clinic. IMRT plans were set up 
using 11 beams and 55 segments. mARC plans for both 
energies were made using one rotation for prostate and two 
rotations for head-and-neck patients, with 4° arclets of 
spaced equidistantly every 8°. The Varian Eclipse treatment 
planning system with the AAA dose algorithm and a 2.5 mm 
dose grid was used for all plans. Plan quality was assessed 
using PTV coverage and sparing of organs at risk. All plans 
were delivered on an anthropomorphic phantom, where 
scattered dose was measured with thermoluminescent 
dosimeters (TLDs), and treatment times were recorded. 
 
Results: All plans were visually assessed by a senior radiation 
oncologist and were deemed acceptable for treatment. Only 
few significant differences were found for PTV coverage and 
OAR sparing. For prostate cancer plans, no significant 
differences in OAR sparing were found except for the 
bladder, which was better spared by mARC than IMRT for 
both beam energies. For head-and-neck cancer cases, the 
mARC technique achieved a higher index of conformity and 
better sparing of the parotids.  
 
 
 
While differences in plan quality were minor, treatment 
times could be drastically reduced by the combination of 
mARC with FFF beams.e average treatment times for 
prostate cancer were reduced from 7 min for 6 MV IMRT to 2-
3 min for FFF mARC. For the complex head-and-neck target 
volume, times were again reduced from ca. 9 min (IMRT, 6 
MV) to 5:30 min (mARC, FFF 7 MV), even though FFF 7 MV 
required significantly more monitor units than 6 MV plans.  
The scattered dose was considerably lower for the mARC as 
compared with IMRT for all plans. For the prostate, scattered 
dose was further reduced by the FFF beam energy. For 
hypopharynx cancer, this effect was partially obscured by the 
higher monitor units. 
 
 
Conclusion: Target volumes of high and of low complexity 
were analysed in this work. For both scenarios, the mARC 
technique achieved plan qualities comparable or even better 
than for IMRT, with a considerable reduction in treatment 
time (ca. 64 % for prostate and 40 % for hypopharynx) and 
scattered dose. 
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Purpose or Objective: To investigate the feasibility of 
hippocampal-sparing radiotherapy for glioblastoma patients 
using volumetric modulated arc therapy (VMAT). Since 
neurocognitive decline has been associated with hippocampal 
dose, hippocampal sparing could potentially improve 
neurological outcome of patients undergoing cranial 
irradiation. 
 
Material and Methods: Datasets of 27 patients who received 
3D-CRT for glioblastoma were included in this planning study. 
Dose distributions for the 3D-CRT plans were calculated in 
Elekta Oncentra Masterplan with a pencil beam algorithm. 
VMAT plans were optimized using the research TPS Hyperion 
V2.44 (equivalent to Elekta Monaco 5.1) which relies on 
Monte Carlo dose calculation. It was attempted to reduce the 
dose to the contralateral hippocampus as much as possible 
without compromising other treatment parameters such as 
target coverage, homogeneity index, conformity index and 
dose to other organs at risk including brain stem, chiasm, 
optic nerve and lenses. Parameters for both techniques were 
compared applying the Wilcoxon signed-rank test. The 
influence of tumor localization on hippocampal dose 
exposure was investigated with the Mann-Whitney U test. The 
correlation between PTV size and hippocampal dose was 
assessed with Spearman’s rank correlation coefficient. 
 
Results: With VMAT compared to 3D-CRT, the median 
reduction of the mean contralateral hippocampus dose was 
56% (p<0.01). Other treatment parameters could be improved 
or at least be kept stable. Particularly, the median V30Gy of 
the brain was reduced from 58.7% to 48.2% (p<0.01). The 
median homogeneity index improved from 0.18 for 3D-CRT to 
0.15 for VMAT (p<0.01), the median conformity index from 
0.70 to 0.80 (p<0.01). For VMAT, a smaller PTV size 
correlated with improved hippocampal sparing (p=0.01). A 
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parietal tumor localization was a predictor for a higher 
contralateral hippocampal dose (p=0.01). 
 
Conclusion: A substantial reduction of the dose to the 
contralateral hippocampus is technically feasible when VMAT 
is used instead of our standard 3D-CRT planning strategy. The 
amount of sparing that can be achieved strongly depends on 
the individual patient geometry. Whether this approach is 
able to conserve the neurocognitive status without 
compromising the oncological outcome for patients with 
glioblastoma needs to be investigated in the setting of 
prospective clinical trials. 
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Purpose or Objective: Bone metastases are a frequent and 
disturbing complication of cancer. The challenge of 
optimizing dose coverage of the concave shape of the sacrum 
along with its close proximity to the rectum, intestines and 
femoral heads lead us to investigate whether the VMAT 
technique is advantageous when compared to 3D treatment. 
 
Material and Methods: Twenty three consecutively treated 
patients with sacral metastases in 2013-2014 were included 
in a comparative treatment-planning study evaluating VMAT 
and 3-D planning. The statistical analysis included the T- 
test, assuming Unequal Variance (one tail). Calculation of the 
p-value for the comparative results applied. Our null 
hypothesis was that VMAT is better than 3D technique, and 
our alternative hypothesis was that 3D technique is superior 
to VMAT. 
 
Results: The PTV coverage was identical in VMAT and 3D 
planning. Median values and V15 for the intestinal exposure 
showed no statistically significant difference between the 3D 
planning and VMAT: 9.28 Gy (SD 2.25) and 47.0 ml (SD 68.62) 
versus 8.97 Gy (SD 2.18) and 18.45 ml (SD 69.56), 
respectively. However, on an individual per case assessment 
it appears that the lower exposure of the bowel depends on 
the small bowel/ sacrum volumes ratio. The benefit for VMAT 
emerges if such a ratio exceeds one. The median values for 
the rectum 3D and VMAT were 11.34 Gy (SD 5.14) and 7.7 Gy 
(SD 2.76), respectively. The median 3D and VMAT exposure of 
the femoral head were 1.78 (SD 2.94) Vs 4.006 (SD 2.1) on 
the left and 1.74 (0.9) Vs 4.26 (SD 1.8) on the right side for 
the 3D and VMAT, respectively. 
 
Conclusion: Good sacral coverage is achievable with either 3-
D or VMAT approaches. VMAT is advantageous vis-à-vis the 
rectal exposure and when relatively large amounts of small 
bowel course through an individual patient's fields. The 3-D 
approach, however, retains benefit for femoral protection, a 
finding that may have implications for patients with arthritis 
and osteopenia. 
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Purpose or Objective: In Conventional Radiotherapy (CRT), 
Total Body Irradiation (TBI) is generally performed at long 
Source Skin Distance using diodes to drive the delivered dose. 
The dose distribution is usually not well assessed (measured 
only in a few points) and was shown to be strongly 
heterogeneous. This technique also leads to acute and late 
toxicity. Helical Tomotherapy (Accuray Inc., Sunnyvale, CA) 
for TBI is implemented in some centers. Compared to CRT, 
Tomotherapy allows the delivery of the prescribed dose with 
a high level of accuracy and homogeneity. Organs-at-risk can 
be spared and the dose distribution is known before the 
treatment. Two technical issues have to be solved. First, the 
patient must be treated using two plans, head first (HF) and 
feet first (FF) due to limited supero-inferior (SI) table 
motion. At the junction of these two plans, the dose must be 
delivered with particular care. Moreover, the planning target 
volume (PTV) is the entire body, including the skin. A safety 
margin in the air surrounding the body should be added to 
take into account setup errors. Using inverse planning, 
however, can result in over-fluence peaks in the skin region. 
The aim of this work is to present our solution for these two 
issues, our optimized planning protocol and our clinical 
results after one year of practice (outcome for 15 patients). 
 
Material and Methods: Patient treatment position is shown 
hereafter. Thermoplastic masks are placed on the head and 
the thorax (not the legs). Two CTs are acquired (HF and FF). 
At the planning station, the whole body (cropped 3 mm under 
the skin) is divided into 10 PTVs. At the junction (~halfway up 
the thighs), 4 PTVs (thickness 2 cm) are drawn to deliver the 
dose with the degraded penumbra methodology: decreased 
dose is delivered during HF plan and increased dose during FF 
plan. Different sets of doses were tested. The resulting dose 
distribution in the presence of simulated set-up errors (SSUE) 
is computed to find the combination that insures optimal 
dose coverage of the junction. Moreover, to insure dose 
coverage of legs in presence of SSUE, several Virtual Boluses 
(VB) were tested. A VB is a bolus added at planning, but not 
present during treatment. Several thicknesses and densities 
were tested on a phantom study: in presence of SSUE, the 
dose coverage and dose increase (due to the methodology) 
were assessed. 
 
 
 
Results: The best combination of PTV doses at the junction is 
presented in table: V95% stays higher than 96% even in the 
case of a SSUE of 1 cm (SI). The optimal VB is an 8 mm thick 
VB (density=0.4). This allows a good coverage (V95%>95%) for 
a large lateral SSUE (up to 2.9 cm). Underestimation of dose 
using this VB (planning vs measure) is 1.5%. 
 
 
Conclusion: This study presents our optimized planning 
parameters. Since November 2014, 15 patients were treated 
with a dose of 2 or 12 Gy. Dose to lungs was limited to 9 Gy. 
